GlassScriptPhysician profile
Brittany Rose Bell
NPI 1972047587
$5,619.61
in general payments reported to CMS, 2019-2025
23 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $314 · 2023: $2,414 · 2024: $1,545 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,074 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,073.79 |
| Education | $231.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.46 | 2022-2025 | |
| Janssen Biotech, INC. | $793.70 | 2022-2025 | Tremfya |
| Genzyme Corporation | $729.96 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $487.72 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $404.66 | 2023-2025 | Ebglyss, Olumiant, Taltz |
| Incyte Corporation | $314.75 | 2022-2025 | Opzelura |
| Pfizer INC. | $308.26 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $294.81 | 2022-2025 | Ilumya, Blu-U |
| Regeneron Healthcare Solutions, INC. | $270.37 | 2023-2025 | Dupixent |
| Amgen INC. | $230.17 | 2022-2024 | Otezla |
| Organogenesis INC. | $217.20 | 2023-2025 | Puraply, Affinity |
| Arcutis Biotherapeutics, INC. | $111.80 | 2024-2025 | Zoryve |
| Boehringer Ingelheim Pharmaceuticals, INC. | $109.34 | 2023-2024 | Spevigo |
| Galderma Laboratories, L.P. | $86.81 | 2023-2025 | Nemluvio |
| Ucb, INC. | $84.16 | 2023-2025 | Bimzelx, Cimzia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $83.73 | 2025 | Vtama |
| Biofrontera INC. | $80.89 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Leo Pharma INC. | $38.72 | 2023-2025 | Anzupgo, Adbry |
| Novartis Pharmaceuticals Corporation | $37.72 | 2024-2025 | |
| Journey Medical Corporation | $24.25 | 2024 | |
| Genentech USA, INC. | $22.65 | 2024 | Actemra |
| Dermavant Sciences, INC. | $20.52 | 2023 | Vtama |
| Verrica Pharmaceuticals INC. | $19.96 | 2025 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.